“Based on these exciting data, we are energized to potentially bring Anidocel to patients in the second half of this year.”

In context

“n the second half of this year, as well as EVOQUE-03, exploring Trodelvy plus pembro, in first-line metastatic PD-L1 high non-small cell lung cancer. Moving to cell therapy on Slide 22 and on behalf of Cindy and the Kite team, I will touch upon some of our updates on our Anidocel program. Notably, we have filed Anidocel based on our update from the phase II IMagine I trial in fourth-line or later relapsed or refractory multiple myeloma at ASH in December. Anidocel demonstrated clinically meaningful efficacy with 96% overall response, including 74% complete response, and 95% measurable residual disease negativity. Additionally, Anidocel demonstrated a predictable and manageable safety profile with no delayed or non-ICANS neurotoxicities and no immune effector cell-associated enterocolitis. Based on these exciting data, we are energized to potentially bring Anidocel to patients in the second half of this year. Longer term, we see additional opportunity for Anidocel with our Phase III IMMAGINE-03 study in second, third, and fourth-line relapsed or refractory multiple myeloma enrolling in record time. We are also planning a pivotal program in newly diagnosed multiple myeloma. With our broader and rapidly advancing clinical development program, we expect Anidocel to potentially reach more patients earlier in the treatment paradigm. Wrapping up on Slide 23, our key milestones for 2026 include five Phase III readouts as well as five FDA decisions for bruleviratide for chronic hepatitis delta, Viclen for virologically suppressed people with HIV, Trodelvy in first-line PD-L1 positive and negative metastatic breast cancer, and Anidocel in fourth-line and later relapsed or refractory multiple myeloma. W”